PRPhilippe Remy

Philippe Remy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philippe Remy has a total of 570 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Levodopa Use and Characteristics of Freezing-of-Gait in Patients With Parkinson Disease in the NS-Park and PPMI Cohorts

    by Raquel Barbosa, Paulo Bastos, Olivier Rascol, Jean-Christophe Corvol, Ory Magne Fabienne, Christine Brefel-Courbon, Clémence Leung, Louise-Laure Mariani, Luc Defebvre, Nicolas Carriere, et al.

    Background and ObjectivesRecent reports have suggested that levodopa exposure may contribute to freezing of gait (FOG), but this relationship remains controversial because of confounding by disease...

  • Open Access

    Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies

    by David Devos, Olivier Rascol, Wassilios G Meissner, Alexandra Foubert-Samier, Simon Lewis, Christine Tranchant, Mathieu Anheim, David Maltête, Philippe Remy, Karla Eggert, et al.

    Background: Reducing nigrostriatal iron overload reduces neuronal loss in Parkinson's disease (PD) models. Objective: Examine the safety and efficacy of deferiprone in reducing motor disability progression in dopaminergic-treated and treatment-naïve patients with early-stage PD. Methods: Two phase II, multicenter studies, SKY and EMBARK, enrolled patients diagnosed with early PD (<3 years from screening). In SKY, patients on stable dopaminergic therapy were randomized 1:1 to one of four dosage (or placebo-matching) cohorts (300, 600, 900, 1200 mg twice daily [BID]) for 9 months. EMBARK enrolled patients on stable dopaminergic therapy or treatment-naïve patients and received 15 mg/kg BID. For both studies, the primary outcome was the change from baseline to month 9 in motor examination score (Movement Disorder Society-Unified Parkinson's Disease Rating Scale [MDS-UPDRS] Part III). ClinicalTrials.gov: NCT02728843; ANZCTR: ACTRN12617001578392. Results: Overall, 140 patients were randomized in SKY (28 per cohort). Thirty-six patients enrolled in EMBARK (27 dopaminergic-treated; 9 treatment-naïve). In the SKY study, all doses showed the same worsening as the placebo group, with the exception of the 600 mg dose, which was associated with non-significant reductions in MDS-UPDRS Part III least-squares mean (LSM) between baseline and 9 months (−2–8 points versus placebo). In EMBARK, LSM (SE) changes from baseline in MDS-UPDRS Part III were nonsignificant (–1.6 [1.7]) and significant (8.3 [3.9]) for dopaminergic-treated and treatment-naïve patients, respectively, the latter indicating disease worsening. Adverse events possibly related to deferiprone were reported in 35.7%–88.9% across all deferiprone groups vs. 42.9% for placebo. Conclusions: SKY and EMBARK studies indicate that deferiprone combined with L-dopa does not provide significant motor function benefit, while the absence of L-dopa treatment worsens symptoms.


  • Long-term health-related quality of life outcomes of adults with pediatric onset of frequently relapsing or steroid-dependent nephrotic syndrome

    by Marie-Sophie Meuleman, Sophie Guilmin-Crépon, Aurélie Hummel, Eric Daugas, Agnès Dumas, Fallou Leye, Jacques Dantal, Claire Rigothier, François Provot, Dominique Chauveau, et al.

    Background Long-term psychosocial outcomes and health-related quality of life (HRQOL) in adults with pediatric onset of frequently relapsing or steroid-dependent idiopathic nephrotic syndrome (FRNS or SDNS) remain to be determined. Methods In this prospective cohort study, 59 adults with pediatric onset of FRNS/SDNS and persistent active glomerular disease in adulthood completed the GEDEPAC-2 questionnaire exploring 11 well-being domains. Data were compared to the French general population (FGP) with standardized incidence ratio ([SIR]; adjusted for period, age, gender). Regression models were performed to identify predictive factors of psychosocial well-being. Results In 82% of cases, the questionnaire was completed while the participants (n = 59; 47 men; median age = 32 years; median number of relapses = 13) were in complete remission (under specific therapy in 76% of cases). Participants had higher educational degree than in the FGP (SIR = 6.3; p < 0.01) and more frequently a managerial occupation (SIR = 3.1; p < 0.01). Social integration was acceptable with regard to marital status and experience of sexual intercourse, but experiences of discrimination were far more frequent (SIR = 12.5; p < 0.01). The SF-12 mental component summary (MCS) score was altered (Z-score = − 0.6; p < 0.01) and mean multidimensional fatigue inventory (MFI-20) global fatigue score appeared high (12). Transfer from pediatric to adult healthcare was followed by a period of discontinued care for 33% of participants. Multivariate analysis revealed a close relationship between MFI-20, physical health, and MCS. Conclusions This study shows that pediatric onset FRNS and SDNS may have a long-term negative impact on mental HRQOL and highlights the impact of fatigue, which is often not adequately considered in routine care. Graphic abstract


  • Open Access

    Automatic segmentation of the striatum and globus pallidus using MIST: Multimodal Image Segmentation Tool

    by Eelke Visser, Max C. Keuken, Gwenaëlle Douaud, Veronique Gaura, Anne-Catherine Bachoud-Levi, Philippe Remy, Birte U. Forstmann, Mark Jenkinson


  • Optimized Quantification of Translocator Protein Radioligand 18F-DPA-714 Uptake in the Brain of Genotyped Healthy Volunteers

    by Sonia Lavisse, Daniel García-Lorenzo, Marie-Anne Peyronneau, Benedetta Bodini, Claire Thiriez, Bertrand Kuhnast, Claude Comtat, Philippe Remy, Bruno Stankoff, Michel Bottlaender

    Translocator protein (TSPO) is expressed at a low level in healthy brain and is upregulated during inflammatory processes that may occur in neurodegenerative diseases. Thus, TSPO may be a suitable in vivo indicator of neurodegeneration. Here, we quantified the 18F-DPA-714 radioligand in healthy TSPO-genotyped volunteers and developed a method to eliminate the need for invasive arterial blood sampling. Methods: Ten controls (7 high-affinity binders [HABs] and 3 mixed-affinity binders [MABs]) underwent 18F-DPA-714 PET with arterial and venous sampling. 18F-DPA-714 binding was quantified with a metabolite-corrected arterial plasma input function, using the 1- and 2-tissue-compartment models (TCMs) as well as the Logan analysis to estimate total volume distribution (VT) in the regions of interest. Alternative quantification methods were tested, including tissue-to-plasma ratio or population-based input function approaches normalized by late time points of arterial or venous samples. Results: The distribution pattern of 18F-DPA-714 was consistent with the known distribution of TSPO in humans, with the thalamus displaying the highest binding and the cerebellum the lowest. The 2-TCM best described the regional kinetics of 18F-DPA-714 in the brain, with good identifiability (percentage coefficient of variation < 5%). For each region of interest, VT was 47.6% ± 6.3% higher in HABs than in MABs, and estimates from the 2-TCM and the Logan analyses were highly correlated. Equilibrium was reached at 60 min after injection. VT calculated with alternative methods using arterial samples was strongly and significantly correlated with that calculated by the 2-TCM. Replacement of arterial with venous sampling in these methods led to a significant but lower correlation. Conclusion: Genotyping of subjects is a prerequisite for a reliable quantification of 18F-DPA-714 PET images. The 2-TCM and the Logan analyses are accurate methods to estimate 18F-DPA-714 VT in the human brain of both HAB and MAB individuals. Population-based input function and tissue-to-plasma ratio with a single arterial sample are promising alternatives to classic arterial plasma input function. Substitution with venous samples is promising but still requires methodologic improvements.


  • Clinical routine use of dopamine transporter imaging in 516 consecutive patients

    by Claire Thiriez, Emmanuel Itti, Gilles Fénelon, Eva Evangelista, Michel Meignan, Pierre Cesaro, Philippe Remy

    [123I]-FP-CIT is a single photon emission computed tomography (SPECT) ligand showing in vivo the loss of dopaminergic terminals in the brain and is now available in the market. Despite several systematic studies in clinically inconclusive cases, the use of such imaging in clinical routine is scarcely reported. We analyzed 516 files of subjects with movement disorders who were consecutively examined using [123I]-FP-CIT scan and determined whether the use of imaging was appropriate and if it improved clinical diagnosis or care of the patient. In addition, we determined if appropriate use was related to subspecialties in Neurology, e.g., movement disorders’ specialists vs. general neurologists, and if appropriate use was increasing over time. Among the 516 scans, 18 % were in agreement with the license, 62 % were classified as appropriate and 37 % were considered inappropriate. A change of management was obvious in 60 % of patients, but in 92 % of those with an appropriate request vs. 13 % of patients with an inappropriate request. Movement disorders’ specialists had more appropriate requests than other practitioners. Eventually, comparing the first 100 vs. the last 100 quantified SPECT, performed more than 2.5 years apart, we found no difference for the appropriateness of the examination. The use of [123I]-FP-CIT imaging in clinical routine does not fit a restrictive license. An inappropriate use is seen in nearly 40 % of cases, which reduces the real cost-effectiveness of the technique suggesting a need for continuing medical education on the topic.


  • [18F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain

    by S. Lavisse, K. Inoue, C. Jan, M. A. Peyronneau, F. Petit, S. Goutal, J. Dauguet, M. Guillermier, F. Dollé, L. Rbah-Vidal, et al.


  • Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

    by Stéphane Palfi, Jean Marc Gurruchaga, G Scott Ralph, Helene Lepetit, Sonia Lavisse, Philip C Buttery, Colin Watts, James Miskin, Michelle Kelleher, Sarah Deeley, et al.